证券代码：600976 证券简称：健民集团 公告编号：2023-003 健民药业集团股份有限公司 关于召开 2022 年度业绩说明会预告公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2022 年年度的经营成 果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范 围内就投资者普遍关注的问题进行回答。 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 03 月 09 日(星期四)至 03 月 15 日(星期三)16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 （ir.jmjt@whjm.com）进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 健民药业集团股份有限公司（以下简称"公司"）将于 2023 年 03 月 15 日发 布公司 2022 年年度报告及其相关公告，为便于广大投资者更全面深入地了解公 司 2022 年年度经营成果、财务状况，公司计划于 2023 年 03 月 16 日 ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥967,670,625.04, representing an increase of 18.98% compared to the same period last year[7]. - The net profit attributable to shareholders for Q3 2022 was ¥127,693,350.60, reflecting a growth of 41.96% year-over-year[7]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥119,572,822.29, up by 45.51% compared to the previous year[7]. - The basic and diluted earnings per share for Q3 2022 were both ¥0.84, an increase of 42.37% year-over-year[10]. - Operating profit for the third quarter of 2022 was CNY 359,007,768.41, up from CNY 285,543,131.38 in the previous year, reflecting a growth of 25.67%[36]. - Net profit attributable to shareholders of the parent company for the third quarter of 2022 was CNY 326,106,974.12, compared to CNY 257,101,116.94 in the same quarter of 2021, representing an increase of 26.83%[38]. - Other income for the first three quarters of 2022 was CNY 28,903,175.26, significantly higher than CNY 7,022,126.55 in the same period of 2021, reflecting an increase of 311.73%[32]. Assets and Liabilities - Total assets at the end of Q3 2022 reached ¥3,247,356,885.89, marking a 14.93% increase from the end of the previous year[10]. - The equity attributable to shareholders at the end of Q3 2022 was ¥1,770,424,510.53, which is a 13.40% increase from the end of the previous year[10]. - The total liabilities increased to CNY 1,469,360,420.72 in 2022 from CNY 1,257,350,034.63 in 2021, marking an increase of 16.83%[30]. - The company's total assets reached CNY 3,247,356,885.89 in 2022, compared to CNY 2,825,602,235.14 in 2021, indicating a growth of 14.92%[32]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥98,752,841.07, down by 48.72% year-over-year[10]. - The net cash flow from operating activities was 98,752,841.07, a decrease of 48.6% compared to 192,572,225.32 from the previous period[41]. - Total cash inflow from investment activities was 851,024,470.25, down from 1,383,991,535.15, indicating a decline of 38.5%[41]. - The net cash flow from investment activities was -77,171,474.55, contrasting with a positive 66,668,478.85 in the previous period[41]. - Cash outflow from financing activities totaled 258,377,642.65, an increase of 40.5% compared to 183,851,338.32 from the previous period[43]. - The net cash flow from financing activities was -132,411,859.75, worsening from -65,909,990.83 in the previous period[43]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 17,999, with the largest shareholder holding 24.13% of the shares[16]. Research and Development - Research and development expenses for the first three quarters of 2022 amounted to CNY 47,325,080.03, significantly higher than CNY 25,621,608.79 in the same period of 2021, indicating a growth of 84.67%[32]. Other Information - The company has not disclosed any new product developments or market expansion strategies in the current report[25]. - There are no significant mergers or acquisitions reported during the period[25].

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 1,827,300,633.45, representing a 1.93% increase compared to CNY 1,792,722,536.20 in the same period last year[22]. - Net profit attributable to shareholders for the first half of 2022 was CNY 198,413,623.52, an increase of 18.70% from CNY 167,152,775.88 in the previous year[22]. - The net cash flow from operating activities increased by 8.24% to CNY 83,969,895.00, up from CNY 77,575,100.99 in the same period last year[22]. - Basic earnings per share for the first half of 2022 were CNY 1.31, up 19.09% from CNY 1.10 in the same period last year[22]. - The company achieved a revenue of 1.827 billion yuan in the reporting period, representing a year-on-year growth of 1.93%[55]. - The pharmaceutical industrial segment generated 904 million yuan, up 2.55% year-on-year, while the pharmaceutical commercial segment reported 916 million yuan, a 0.92% increase[55]. - Net profit attributable to shareholders reached 198 million yuan, reflecting an 18.7% increase, driven by a 19% growth in prescription drug revenue and increased government subsidies[55]. Assets and Liabilities - The company's total assets at the end of the reporting period were CNY 2,928,516,347.62, a 3.64% increase from CNY 2,825,602,235.14 at the end of the previous year[22]. - The net assets attributable to shareholders at the end of the reporting period were CNY 1,640,424,302.07, reflecting a 5.07% increase from CNY 1,561,213,992.01 at the end of the previous year[22]. - The company’s cash and cash equivalents decreased by 32.13% to CNY 202,502,100.37, primarily due to increased financial investments[81]. - The company’s inventory decreased by 30.00% to CNY 155,210,825.11, as sales from previous stock were realized[81]. - The company’s total liabilities decreased by 50.69% in contract liabilities to CNY 18,173,364.77, reflecting a reduction in advance payments received from customers[83]. Research and Development - The company plans to accelerate R&D investment and product development in response to national policies encouraging innovation and high-end manufacturing[48]. - The company increased R&D investment, with a total of 127 effective patents by the end of the reporting period[73]. - Research and development expenses increased significantly to ¥30,167,520.08 in the first half of 2022, up from ¥16,010,356.99 in the same period of 2021, marking an increase of approximately 88.5%[193]. Market and Industry Trends - The growth in revenue was primarily driven by the increase in prescription drug product line sales[22]. - The pharmaceutical manufacturing industry in China saw a revenue increase of 20.1% year-on-year in 2021, with total revenue reaching RMB 2,928.85 billion[30]. - The company operates in a growing industry with 8,677 pharmaceutical manufacturing enterprises as of May 2022, an increase of 445 from the previous year[29]. - The rapid development of pharmaceutical e-commerce has been driven by changes in consumer behavior due to the pandemic, leading to a new competitive landscape between traditional and online drug distribution[38]. Environmental Responsibility - The company has implemented a comprehensive environmental monitoring and management system, including emergency response plans for environmental incidents[125]. - The company’s production processes utilize clean energy, with emissions meeting national standards for air pollutants[123]. - The company has implemented measures to reduce carbon emissions, including the use of clean energy and the automation of production processes[137]. - The company has not faced any administrative penalties for environmental violations during the reporting period[130]. Corporate Governance and Shareholder Information - The company did not distribute profits or increase capital reserves during the reporting period[7]. - The integrity status of the company and its controlling shareholders is good, with no unfulfilled court judgments or significant overdue debts[147]. - The total number of shares after the change is 153,398,600, with a decrease of 531,200 shares in restricted shares[157]. - The company has a total of 531,200 restricted stocks that have been unlocked and are now tradable, with the next unlock date set for May 24, 2024[160].

证券代码：600976 证券简称：健民集团 公告编号：2022-034 健民药业集团股份有限公司 关于参加 2022 年湖北辖区上市公司投资者集体 接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2022 年 6 月 16 日（星期四）14：00-16：00 会议召开地点："全景• 路演天下"（http://rs.p5w.net）网络平台 会议召开方式：网络文字互动 预征集投资者提问的相关安排：投资者可在 2022 年 6 月 15 日（星期三） 16:00 前 登 录 http://rs.p5w.net/zj/ " 问 题 征 集 专 题 " 或 通 过 公 司 邮 箱 （ir.jmjt@whjm.com）进行提问，公司将在本次活动上就投资者普遍关注的问题 进行回答。 为进一步加强与广大投资者的互动交流，根据湖北省上市公司协会《关于举 办2022年湖北辖区上市公司投资者集体接待日暨2021年度业绩说明会活动的通 知》，健民药业集团股份有限公司（以下简称"公司"）将于 20 ...

Financial Performance - The company's operating revenue for Q1 2022 was ¥917,942,461.38, representing a year-on-year increase of 9.10%[5] - The net profit attributable to shareholders for Q1 2022 was ¥88,709,237.44, reflecting a growth of 25.95% compared to the same period last year[9] - Basic and diluted earnings per share for Q1 2022 were both ¥0.58, an increase of 26.90% year-on-year[5] - Total operating revenue for Q1 2022 was 917,942,461.38, an increase of 9.1% from 841,378,502.19 in Q1 2021[33] - Net profit for Q1 2022 reached 88,756,974.61, representing a 25.6% increase compared to 70,676,823.76 in Q1 2021[34] - Earnings per share for Q1 2022 was 0.58, compared to 0.46 in Q1 2021[34] Cash Flow - The net cash flow from operating activities decreased by 408.03% year-on-year, primarily due to increased cash outflows for procurement, advertising, salaries, and taxes[8] - Cash inflow from operating activities for Q1 2022 was $723,829,244.73, compared to $713,106,891.34 in Q1 2021, showing a slight increase[39] - Cash outflow from operating activities increased to $844,665,241.69 in Q1 2022 from $673,878,203.63 in Q1 2021, resulting in a net cash flow from operating activities of -$120,835,996.96[39] - The net increase in cash and cash equivalents for Q1 2022 was -$26,300,660.75, compared to an increase of $31,229,249.72 in Q1 2021[40] - The ending balance of cash and cash equivalents for Q1 2022 was $252,062,052.72, down from $93,387,531.81 in Q1 2021[40] Assets and Liabilities - Total assets at the end of Q1 2022 amounted to ¥2,970,623,182.21, up 5.13% from the end of the previous year[8] - Total liabilities increased to ¥1,272,521,661.72 from ¥1,220,054,426.89, showing a rise of approximately 4.3%[27] - Total assets reached RMB 2,970,623,182.21, compared to RMB 2,825,602,235.14 at the end of the previous year[27] - Total liabilities as of the reporting date were 1,311,756,072.56, up from 1,257,350,034.63 in the previous period[29] Shareholder Equity - Shareholders' equity attributable to the parent company increased by 5.80% year-on-year, reaching ¥1,651,781,163.98[8] - Total equity attributable to shareholders was 1,651,781,163.98, an increase from 1,561,213,992.01[29] Research and Development - The company increased its R&D expenses, reflecting a commitment to enhancing innovation and product development[12] - Research and development expenses for Q1 2022 were 17,182,920.20, significantly higher than 8,243,887.67 in Q1 2021[33] Investment Income - The increase in investment income was attributed to higher returns from joint ventures compared to the previous year[12] - Investment income for Q1 2022 was 40,608,498.78, an increase from 30,781,913.88 in Q1 2021[33] - The company reported a significant increase in cash received from investment income, amounting to $82,013,315.69 in Q1 2022, compared to $7,220,563.53 in Q1 2021[39] Other Financial Metrics - The weighted average return on equity for Q1 2022 was 5.53%, an increase of 0.27 percentage points compared to the previous year[5] - Non-recurring gains and losses for the period totaled ¥8,902,686.11, after accounting for tax impacts[12] - Deferred income increased to 30,169,805.46 from 27,717,201.29[29] - Employee compensation payments rose to $79,759,634.97 in Q1 2022 from $61,626,747.76 in Q1 2021, indicating increased labor costs[39]

Financial Performance - The company's operating revenue for 2021 was RMB 3,278,183,640.34, representing a year-on-year increase of 33.48%[24]. - The net profit attributable to shareholders for 2021 was RMB 324,736,841.19, a significant increase of 119.73% compared to the previous year[24]. - The net cash flow from operating activities increased by 106.46% to RMB 259,183,455.41, driven by growth in sales scale[24]. - The total assets at the end of 2021 were RMB 2,825,602,235.14, reflecting a year-on-year increase of 16.90%[24]. - The net assets attributable to shareholders at the end of 2021 were RMB 1,561,213,992.01, up 18.55% from the previous year[24]. - Basic earnings per share (EPS) for 2021 was CNY 2.13, up 121.88% from CNY 0.96 in 2020[27]. - The weighted average return on equity (ROE) increased to 21.86%, up 10.13 percentage points from 11.73% in 2020[27]. - The company reported a quarterly revenue of CNY 672.16 million in Q4 2021, with a decline in net profit attributable to shareholders to CNY 67.64 million due to year-end impairment provisions[28]. Revenue Segmentation - Revenue from the pharmaceutical manufacturing segment grew by 43.92% year-on-year, while pharmaceutical commerce revenue increased by 24.48%[24]. - The pharmaceutical industry segment generated CNY 1,682.25 million in revenue, up from CNY 1,174.35 million in 2020[40]. - In 2021, the company achieved a 43.92% year-on-year growth in pharmaceutical industrial revenue, with OTC sales increasing by 51.28% and Rx sales growing by 36.23%[41]. - The company reported a decrease of 31.02% in revenue from other business segments[24]. - The pharmaceutical commercial segment reached 1,588.1850 million RMB, growing by 24.48%[59]. Product Development and R&D - The company initiated 25 new drug research projects in 2021, including 5 pediatric formulations, and received 1 new drug certificate[45]. - The company launched new products such as "Zhuo Bei Gao" children's growth milk powder and expanded its e-commerce business[45]. - The company has 39 ongoing research projects, including 25 new drug development projects, 10 secondary development projects, and 4 health food projects[110]. - The company is committed to enhancing its R&D capabilities and expanding its product pipeline in the future[119]. - The company plans to increase R&D investment and improve the conversion rate of research outcomes in response to the rapid inclusion of innovative drugs in the medical insurance system[54]. Market Strategy and Expansion - The company plans to focus on product development and marketing strategies to enhance competitiveness in response to industry changes[39]. - The company aims to maintain rapid growth in operating performance and asset quality through refined management and cost control[39]. - The company aims to enhance its position in the national supply chain by focusing on talent development and core technology breakthroughs, addressing critical issues in the pharmaceutical industry[49]. - The company is committed to high-quality innovation and increasing R&D investment in response to national policies encouraging innovation and high-end manufacturing[49]. - The company is actively exploring innovative business models, including traditional Chinese medicine services and health tourism[143]. Risk Management - The company has not identified any significant risks that could materially affect its operations during the reporting period[9]. - The company faces risks related to product concentration, with three key products accounting for over 50% of industrial revenue, necessitating a focus on product diversification[144]. - The company faces risks from fluctuations in raw material prices, particularly traditional Chinese medicine materials, which are affected by natural conditions and market supply-demand dynamics[147]. - The implementation of centralized procurement for traditional Chinese medicine by the National Medical Insurance Administration in 2022 poses a risk of product price declines[147]. - New drug development involves high investment and risk, with potential challenges in clinical efficacy and market acceptance[147]. Corporate Governance and Management - The company held 6 shareholder meetings and 15 board meetings, reviewing a total of 84 proposals[151]. - The company disclosed 146 pieces of information in 2021, including 4 regular reports and 77 temporary announcements, achieving a B rating from the Shanghai Stock Exchange for information disclosure[154]. - The company has established a management system for insider information, ensuring compliance and confidentiality[154]. - The company maintains open communication with investors through various channels, enhancing investor relations management[154]. - The total pre-tax remuneration for the chairman, He Qin, was CNY 1.0136 million, with a significant increase in shareholding from 0 to 318,720 shares due to equity incentives[162]. Future Outlook - The company provided a forward guidance of 10% revenue growth for the next fiscal year, projecting revenues of $1.32 billion[167]. - The company plans to invest $50 million in new technology to improve operational efficiency over the next two years[167]. - The company anticipates significant growth in the domestic pharmaceutical market due to increasing healthcare awareness and an aging population[139]. - The company plans to enhance market forecasting and strategic procurement to mitigate raw material supply risks[147]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 300 million RMB allocated for potential deals[171].

Financial Performance - The company's revenue for Q3 2021 reached ¥813,301,731.81, representing a year-on-year increase of 40.45%[6] - Net profit attributable to shareholders for Q3 2021 was ¥89,948,341.06, up 31.10% compared to the same period last year[6] - The net profit for the first nine months of 2021 increased by 104.36% year-on-year, driven by the sales growth of key products such as Longmu Bone Strengthening Granules[9] - Basic earnings per share for Q3 2021 were ¥0.59, reflecting a 30.78% increase year-on-year[8] - Net profit for the third quarter of 2021 was ¥257,844,521.81, up from ¥126,379,141.72 in the same quarter of 2020, reflecting a growth of approximately 103.5%[30] - The total comprehensive income for the third quarter of 2021 was CNY 257,844,521.81, compared to CNY 126,379,141.72 in the same period of 2020, representing a significant increase[31] - The company’s total comprehensive income attributable to the parent company for the third quarter of 2021 was CNY 257,101,116.94, compared to CNY 125,808,429.31 in the same period of 2020, reflecting a growth of 104.5%[31] Cash Flow and Assets - The operating cash flow for the first nine months of 2021 saw a significant increase of 193.84% year-on-year, attributed to improved collection management and increased sales receipts[9] - Cash inflow from operating activities for the first nine months of 2021 was CNY 2,588,679,046.80, compared to CNY 1,590,421,916.28 in the same period of 2020, reflecting an increase of 62.8%[34] - The net cash flow from operating activities for the first nine months of 2021 was CNY 192,572,225.32, compared to CNY 65,537,390.81 in the previous year, showing a growth of 194.5%[34] - Cash and cash equivalents at the end of the third quarter of 2021 totaled CNY 255,488,995.43, up from CNY 101,394,870.28 at the end of the same period in 2020, representing an increase of 151.1%[35] - Total assets at the end of Q3 2021 amounted to ¥2,677,610,352.53, a 10.77% increase from the end of the previous year[8] - The total assets as of the third quarter of 2021 amounted to ¥2,677,610,352.53, compared to ¥2,417,176,831.31 in the previous year, marking an increase of about 10.7%[26] Shareholder Information - Total number of common shareholders at the end of the reporting period is 12,082[16] - The largest shareholder, Huali Pharmaceutical Group Co., Ltd., holds 37,014,073 shares, accounting for 24.13% of total shares[16] - The company reported a total equity attributable to shareholders of ¥1,486,227,513.99 at the end of Q3 2021, a 12.86% increase from the previous year[8] - The company's total equity reached ¥1,493,324,595.33 in the third quarter of 2021, compared to ¥1,323,261,471.50 in the previous year, indicating an increase of about 12.9%[26] Expenses and Liabilities - Total operating costs for the third quarter of 2021 were ¥2,435,006,561.46, compared to ¥1,561,388,126.38 in the previous year, indicating an increase of about 55.8%[28] - Total liabilities for the third quarter of 2021 were ¥1,184,285,757.20, an increase from ¥1,093,915,359.81 in the same period of 2020, representing a growth of approximately 8.3%[26] - Research and development expenses for the third quarter of 2021 were ¥25,621,608.79, slightly up from ¥24,521,743.39 in the same period of 2020, showing a growth of approximately 4.5%[28] Inventory and Receivables - The company reported accounts receivable of RMB 543,293,381.61, significantly up from RMB 161,912,097.21 in the previous year[22] - Inventory decreased to RMB 123,496,590.88 from RMB 228,998,205.16 year-over-year[22] Share Repurchase and Incentives - The company plans to repurchase shares with a total fund of no less than RMB 25 million and no more than RMB 40 million, having already repurchased 1,432,001 shares[19] - The total number of shares repurchased represents 0.93% of the company's total share capital[19] - The company has granted a total of 1,062,401 restricted stocks to 7 eligible incentive objects as part of its 2021 restricted stock incentive plan[19]

Financial Performance - The company's operating revenue for the first half of 2021 was CNY 1,792,722,536.20, representing a 74.50% increase compared to CNY 1,027,323,574.04 in the same period last year[26]. - The net profit attributable to shareholders of the listed company reached CNY 167,152,775.88, a significant increase of 192.24% from CNY 57,196,566.32 in the previous year[26]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 158,928,248.12, up 203.40% from CNY 52,382,254.32 year-on-year[26]. - The net cash flow from operating activities was CNY 77,575,100.99, which is a 176.09% increase compared to CNY 28,097,696.31 in the same period last year[26]. - The company's basic earnings per share (EPS) for the first half of the year is CNY 1.10, a 197.30% increase compared to CNY 0.37 in the same period last year[28]. - The weighted average return on equity (ROE) rose to 12.1%, an increase of 7.45 percentage points from 4.65% in the previous year[28]. - The basic earnings per share after deducting non-recurring gains and losses is CNY 1.04, reflecting a 205.88% increase from CNY 0.34 in the same period last year[28]. Revenue Growth - The company's revenue grew by 74.50% year-on-year, with pharmaceutical manufacturing revenue up 73.24% and pharmaceutical commerce revenue up 75.76%[28]. - The net profit attributable to shareholders increased by 192.24% year-on-year, primarily driven by increased revenue from key products such as Longmu Zhuanggu Granules[28]. - Longmu Bone Strengthening Granules sold over 20 million bags during the reporting period, significantly contributing to revenue growth[64]. Asset and Equity Changes - The net assets attributable to shareholders of the listed company at the end of the reporting period were CNY 1,392,573,679.47, reflecting a 5.75% increase from CNY 1,316,907,795.03 at the end of the previous year[26]. - The total assets of the company amounted to CNY 2,584,719,184.14, which is a 6.93% increase compared to CNY 2,417,176,831.31 at the end of the previous year[26]. - The company's equity attributable to shareholders increased to approximately $1.39 billion, up from $1.32 billion, reflecting a growth of about 5.7%[172]. Cost and Expense Management - Operating costs increased to ¥1,044,479,932.20, reflecting a 73.8% rise from ¥600,966,639.75 in the previous year[69]. - The pharmaceutical segment's revenue grew by 69.50%, with a gross margin increase of 2.69 percentage points to 72.64%[72]. - The company is focusing on optimizing production processes and enhancing quality while controlling costs, with a reported cost growth of 61.24% being lower than revenue growth[69]. Research and Development - The company has 30 new drug projects under research, which may face high investment and risk challenges[95]. - R&D efforts are progressing steadily, with several pediatric formulation projects completing critical testing phases and new drug clinical research advancing as planned[66]. - Research and development expenses for the first half of 2021 were ¥16,010,356.99, slightly up from ¥15,633,456.53 in the previous year, indicating a growth of about 2.4%[182]. Environmental Management - The company has established an environmental management system that includes regular monitoring and reporting of pollutant discharge concentrations and volumes[117]. - The company reported that all emissions from Yekai Thai Pharmaceutical are within the permitted limits, with no violations of environmental regulations during the reporting period[118]. - The company has committed to continuous improvement in environmental management and energy conservation efforts[117]. Market Position and Strategy - The company is positioned to benefit from ongoing reforms in the pharmaceutical industry, including the integration of medical insurance and healthcare systems[37]. - The company is actively expanding its market presence through new product development and marketing strategies, including the launch of OTC products like Bian Tong Capsules[66]. - The company focuses on pediatric, gynecological, and geriatric treatment areas, offering nearly 500 varieties of products[55]. Shareholder Information - The total number of shares held by directors and executives increased significantly due to stock incentives, with notable increases for key individuals such as He Qin and Wang Jun[159]. - The largest shareholder, Huali Pharmaceutical Group Co., Ltd., holds 38,484,073 shares, accounting for 25.09% of the total shares[151]. - The company has repurchased a total of 1,432,001 shares, representing 0.93% of the total share capital, with a total expenditure of approximately 39.99 million RMB[141].

证券代码：600976 证券简称：健民集团 公告编号：2021-043 健民药业集团股份有限公司 关于参加湖北上市公司 2021 年度投资者网上集体接 待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2021 年 6 月 24 日（星期四）15：30-17：00 会议召开地点："全景• 路演天下"（http://rs.p5w.net）网络平台 会议召开方式：网络文字互动 会议问题征集：投资者可在 2021 年 6 月 23 日（星期三）16:00 前将关 注的问题发送至公司电子邮箱（ir.jmjt@whjm.com），公司将在湖北上市公司 2021 年度投资者网上集体接待日活动中就投资者普遍关注的问题进行回答。 为进一步加强与广大投资者的互动交流，根据湖北省上市公司协会《关于举 办"真诚沟通，互信共赢"湖北上市公司 2021 年度投资者网上集体接待日活动 的通知》，健民药业集团股份有限公司（以下简称"公司"）将于 2021 年 6 月 24 日下午 15：30-17：00 参 ...

Financial Performance - Net profit attributable to shareholders increased by 272.49% to CNY 70,434,076.46 compared to the same period last year[11]. - Operating income rose by 91.06% to CNY 841,378,502.19 compared to the same period last year[9]. - Basic earnings per share increased by 283.33% to CNY 0.46 compared to the same period last year[9]. - The company reported a significant increase in sales revenue, with cash received from sales reaching CNY 684,257,838.20 in Q1 2021, up from CNY 432,840,758.19 in Q1 2020, representing a growth of approximately 58%[48]. - Net profit for Q1 2021 reached CNY 53,792,494.34, up 246.5% from CNY 15,518,574.73 in the same period last year[43]. - The total comprehensive income for Q1 2021 was CNY 53,792,494.34, compared to CNY 15,518,574.73 in Q1 2020, marking a growth of 246.5%[44]. Cash Flow - Net cash flow from operating activities increased by 481.57% to CNY 39,228,687.71 compared to the same period last year[9]. - In Q1 2021, the cash inflow from operating activities was CNY 713,106,891.34, a significant increase from CNY 439,803,206.59 in Q1 2020, representing a growth of approximately 62.2%[48]. - The net cash flow from operating activities for Q1 2021 was CNY 39,228,687.71, compared to a negative cash flow of CNY -10,280,908.25 in Q1 2020, indicating a turnaround in performance[48]. - The total cash inflow from investment activities in Q1 2021 was CNY 459,025,978.35, up from CNY 203,774,258.79 in Q1 2020, marking an increase of about 125.5%[49]. - The net cash flow from investment activities for Q1 2021 was CNY 32,635,513.05, a recovery from a negative cash flow of CNY -16,256,165.94 in Q1 2020[49]. Assets and Liabilities - Total assets increased by 6.06% to CNY 2,563,552,582.41 compared to the end of the previous year[9]. - The total liabilities increased by 24.23% to RMB 571,661,463.81, primarily due to increased marketing expenses related to higher sales[20]. - The company's total assets amounted to approximately CNY 2.56 billion, an increase from CNY 2.42 billion at the end of 2020, representing a growth of about 6%[30]. - The total liabilities of the company increased to CNY 1.21 billion from CNY 1.09 billion, marking an increase of about 11%[30]. Shareholder Information - The total number of shareholders at the end of the reporting period was 8,997[14]. - The largest shareholder, Huali Pharmaceutical Group Co., Ltd., holds 25.09% of the shares[14]. - The company repurchased a total of 1,432,001 shares, accounting for 0.93% of the total share capital, at an average price of RMB 27.93 per share, totaling RMB 39,992,706.26[22]. - The company plans to utilize the repurchased shares within 36 months; otherwise, it will cancel the unused shares as per legal requirements[23]. Research and Development - Research and development expenses rose by 85.30% to RMB 8,243,887.67, reflecting increased investment in R&D activities[20]. - Research and development expenses for Q1 2021 were ¥8,243,887.67, up from ¥4,448,948.50 in Q1 2020, reflecting an increase of 85.5%[40]. Tax and Expenses - The company experienced a 140.19% increase in income tax expenses, amounting to RMB 7,424,556.89, due to profit growth[20]. - The tax expenses for Q1 2021 were CNY 4,249,851.11, compared to CNY 2,156,219.07 in Q1 2020, indicating higher profitability[43].